Marcin Trojanowski, MD
Rheumatology · Boston, MANPI 1730348111
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,235 of the $15,638 with a category attached, or 71.8%. Boehringer Ingelheim accounts for 76.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $11,136, 8.0 times the $1,388 reported in 2019.
Across 33 payments — averaging $473.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$12K
- Novartis$2K
- CSL Behring$1K
- Sandoz$20
Across 75 payments — averaging $3770.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$120K
- Kadmon Corporation LLC$62K
- Boehringer Ingelheim$34K
- Sanofi US Services Inc.$28K
- CSL Behring$18K
- Novartis$10K
- plus $10K from 2 others
What the payments were for
- Consulting fees$11,23572%
- Travel & lodging$2,67017%
- Food & beverage$1,73411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $12,022 |
| Novartis | 15 | $2,208 |
| CSL Behring | 7 | $1,388 |
| Sandoz | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,638 in reported general payments places this provider in the 80th percentile of 265 rheumatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 96 | $763,049 |
| Xeljanz XrTofacitinib Citrate | 66 | $363,088 |
| Actemra ActpenTocilizumab | 53 | $276,563 |
| Enbrel SureclickEtanercept | 33 | $236,169 |
| Humira(Cf) PenAdalimumab | 26 | $216,107 |
| RinvoqUpadacitinib | 25 | $154,552 |
| XeljanzTofacitinib Citrate | 21 | $121,862 |
| Cyltezo(Cf) PenAdalimumab-Adbm | 13 | $85,932 |
| OrenciaAbatacept | 14 | $80,143 |
| MeloxicamMeloxicam, Submicronized | 12 | $23,424 |
| Mycophenolate Mofetil | 143 | $15,089 |
| OtrexupMethotrexate/Pf | 13 | $8,712 |
| EliquisApixaban | 14 | $8,184 |
| MethotrexateMethotrexate Sodium | 273 | $5,993 |
| RasuvoMethotrexate/Pf | 12 | $5,950 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Boston
- Marilyn PikeBoston$1.4M
- John StoneBoston$926K
- Lee SimonBoston$600K
- Jeffrey SparksBoston$299K
- Tanya LaidlawBoston$244K
- Tuhina NeogiBoston$242K
- Michael WeinblattBoston$228K
- Michael BrennerBoston$115K
- Zachary WallaceBoston$106K
- Flavia CastelinoBoston$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.